文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

针对自噬的促死亡和促存活功能,将其作为癌症治疗的新策略。

Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer.

机构信息

Division of Medicinal Chemistry, College of Pharmacy, The University of Texas at Austin, Austin, TX, USA.

出版信息

Autophagy. 2010 Apr;6(3):322-9. doi: 10.4161/auto.6.3.11625. Epub 2010 Apr 26.


DOI:10.4161/auto.6.3.11625
PMID:20224296
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2914492/
Abstract

Autophagy is an evolutionarily conserved lysosomal pathway for degrading cytoplasmic proteins, macromolecules, and organelles. While autophagy has become one of the most attractive topics in cancer research, the current autophagy literature is often viewed as confusing, because of its association with apparently contradictory roles, such as survival and cell death. Autophagy can serve as a tumor suppressor, as a partial reduction in autophagic capacity or defective autophagy (e.g., heterozygous knockdown BECN1 (+/-) in mice) provides an oncogenic stimulus, causing malignant transformation and spontaneous tumors. In addition, autophagy seems to function as a protective cell survival mechanism against environmental and cellular stress (e.g., nutrient deprivation, hypoxia and therapeutic stress) and causes resistance to antineoplastic therapies. Recent studies have demonstrated that the inhibition of autophagy in cancer cells may be therapeutically beneficial in some circumstances, as it can sensitize cancer cells to different therapies, including DNA-damaging agents, antihormone therapies (e.g., tamoxifen), and radiation therapy. This supports the hypothesis that inhibiting autophagy can negatively influence cancer cell survival and increase cell death when combined with anticancer agents, providing a therapeutic advantage against cancer. On the other hand, the induction of autophagy by the inhibition of anti-autophagic proteins, such as Bcl-2, PKCdelta, and tissue transglutaminase 2 (TG2), may lead to autophagic cell death in some apoptosis-resistant cancers (i.e., breast and pancreatic cancers), indicating that the induction of autophagy alone may also be used as a potential therapy. Overall, the data suggest that, depending on the cellular features, either the induction or the inhibition of autophagy can provide therapeutic benefits to patients and that the design and synthesis of the first-generation modulators of autophagy may provide the tools for proof of concept experiments and the impetus for translational studies that may ultimately lead to new therapeutic strategies in cancer.

摘要

自噬是一种进化上保守的溶酶体途径,用于降解细胞质蛋白、大分子和细胞器。虽然自噬已成为癌症研究中最具吸引力的课题之一,但由于其与明显矛盾的作用(如生存和细胞死亡)有关,当前的自噬文献往往被认为令人困惑。自噬可以作为肿瘤抑制因子,因为自噬能力的部分降低或缺陷的自噬(例如,小鼠中 BECN1 杂合敲低(+/−))提供了致癌刺激,导致恶性转化和自发性肿瘤。此外,自噬似乎作为一种针对环境和细胞应激(例如,营养剥夺、缺氧和治疗性应激)的保护性细胞存活机制发挥作用,并导致对抗肿瘤治疗的耐药性。最近的研究表明,在某些情况下,抑制癌细胞中的自噬可能具有治疗益处,因为它可以使癌细胞对不同的治疗方法(包括 DNA 损伤剂、抗激素治疗(例如,他莫昔芬)和放射治疗)敏感。这支持了这样一种假设,即抑制自噬可以在与抗癌药物联合使用时对癌细胞的存活产生负面影响并增加细胞死亡,从而为癌症提供治疗优势。另一方面,通过抑制抗自噬蛋白(如 Bcl-2、PKCdelta 和组织转谷氨酰胺酶 2(TG2))诱导自噬可能导致一些抗凋亡癌症(即乳腺癌和胰腺癌)中的自噬细胞死亡,表明单独诱导自噬也可能被用作一种潜在的治疗方法。总体而言,数据表明,根据细胞特征,诱导或抑制自噬都可以为患者提供治疗益处,并且自噬的第一代调节剂的设计和合成可能为概念验证实验提供工具,并为转化研究提供动力,最终可能导致癌症的新治疗策略。

相似文献

[1]
Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer.

Autophagy. 2010-4-26

[2]
Autophagy: friend or foe in breast cancer development, progression, and treatment.

Int J Breast Cancer. 2011

[3]
PKC delta and tissue transglutaminase are novel inhibitors of autophagy in pancreatic cancer cells.

Autophagy. 2007

[4]
Tissue transglutaminase inhibits autophagy in pancreatic cancer cells.

Mol Cancer Res. 2007-3

[5]
Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment.

Cell Cycle. 2010-9-9

[6]
The role of autophagy in liver cancer: molecular mechanisms and potential therapeutic targets.

Biochim Biophys Acta. 2013-8

[7]
Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition.

Cancer. 2020-8-1

[8]
BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells.

Oncotarget. 2016-2-23

[9]
Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling.

J Biol Chem. 2006-12-1

[10]
Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer.

PLoS One. 2013-10-11

引用本文的文献

[1]
Targeting Cancer Cell Fate: Apoptosis, Autophagy, and Gold Nanoparticles in Treatment Strategies.

Curr Issues Mol Biol. 2025-6-14

[2]
Nanomedicine Approaches for Autophagy Modulation in Cancer Therapy.

Small Sci. 2025-4-11

[3]
Aniline TFPA enhances camptothecin-induced anti-NSCLC by modulating oxidative stress and impairing autophagy.

Cancer Cell Int. 2025-3-7

[4]
The role of SIRT1 in autophagy and drug resistance: unveiling new targets and potential biomarkers in cancer therapy.

Front Pharmacol. 2024-9-30

[5]
Evaluation of autophagy related ATG4B gene, protein and miR-655-3p expression levels in endometrial cancer and hyperplasia.

J Gynecol Oncol. 2025-3

[6]
Targeting endocytosis to sensitize cancer cells to programmed cell death.

Biochem Soc Trans. 2024-8-28

[7]
The upregulation of TGM2 is associated with poor prognosis and the shaping of the inflammatory tumor microenvironment in lung squamous cell carcinoma.

Am J Cancer Res. 2024-6-15

[8]
The impact of nanomaterials on autophagy across health and disease conditions.

Cell Mol Life Sci. 2024-4-17

[9]
Nanoplatform-Mediated Autophagy Regulation and Combined Anti-Tumor Therapy for Resistant Tumors.

Int J Nanomedicine. 2024

[10]
The Emerging Roles of the Metabolic Regulator G6PD in Human Cancers.

Int J Mol Sci. 2023-12-7

本文引用的文献

[1]
AMPK-mediated autophagy inhibits apoptosis in cisplatin-treated tumour cells.

J Cell Mol Med. 2009-9

[2]
Regulation of autophagy through multiple independent hypoxic signaling pathways.

Curr Mol Med. 2009-5

[3]
ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy.

J Biol Chem. 2009-5-1

[4]
Silencing of elongation factor-2 kinase potentiates the effect of 2-deoxy-D-glucose against human glioma cells through blunting of autophagy.

Cancer Res. 2009-3-15

[5]
TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells.

EMBO J. 2009-3-18

[6]
DAP-kinase-mediated phosphorylation on the BH3 domain of beclin 1 promotes dissociation of beclin 1 from Bcl-XL and induction of autophagy.

EMBO Rep. 2009-3

[7]
Cadmium toxicity toward autophagy through ROS-activated GSK-3beta in mesangial cells.

Toxicol Sci. 2009-3

[8]
The pivotal role of c-Jun NH2-terminal kinase-mediated Beclin 1 expression during anticancer agents-induced autophagy in cancer cells.

Oncogene. 2009-2-12

[9]
Involvement of PKC signal pathways in oridonin-induced autophagy in HeLa cells: a protective mechanism against apoptosis.

Biochem Biophys Res Commun. 2009-1-9

[10]
Association of autophagy defect with a malignant phenotype and poor prognosis of hepatocellular carcinoma.

Cancer Res. 2008-11-15

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索